Genovis AB (publ.) GENO.ST Stock
Genovis AB (publ.) Price Chart
Genovis AB (publ.) GENO.ST Financial and Trading Overview
Genovis AB (publ.) stock price | 30.4 SEK |
Previous Close | 52.9 SEK |
Open | 52.9 SEK |
Bid | 52.3 SEK x 0 |
Ask | 52.6 SEK x 0 |
Day's Range | 52.4 - 53.1 SEK |
52 Week Range | 31.15 - 71.8 SEK |
Volume | 9.38K SEK |
Avg. Volume | 75.51K SEK |
Market Cap | 3.44B SEK |
Beta (5Y Monthly) | 1.701149 |
PE Ratio (TTM) | 76.08696 |
EPS (TTM) | 0.83 SEK |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 82 SEK |
GENO.ST Valuation Measures
Enterprise Value | 3.44B SEK |
Trailing P/E | 76.08696 |
Forward P/E | 12.209302 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 24.158983 |
Price/Book (mrq) | 20.215633 |
Enterprise Value/Revenue | 24.175 |
Enterprise Value/EBITDA | 68.865 |
Trading Information
Genovis AB (publ.) Stock Price History
Beta (5Y Monthly) | 1.701149 |
52-Week Change | 14.00% |
S&P500 52-Week Change | 20.43% |
52 Week High | 71.8 SEK |
52 Week Low | 31.15 SEK |
50-Day Moving Average | 57.4 SEK |
200-Day Moving Average | 50.29 SEK |
GENO.ST Share Statistics
Avg. Volume (3 month) | 75.51K SEK |
Avg. Daily Volume (10-Days) | 73.1K SEK |
Shares Outstanding | 65.47M |
Float | 55.1M |
Short Ratio | N/A |
% Held by Insiders | 18.51% |
% Held by Institutions | 45.04% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 29.83% |
Operating Margin (ttm) | 33.07% |
Gross Margin | 88.94% |
EBITDA Margin | 35.10% |
Management Effectiveness
Return on Assets (ttm) | 17.12% |
Return on Equity (ttm) | 28.57% |
Income Statement
Revenue (ttm) | 142.26M SEK |
Revenue Per Share (ttm) | 2.17 SEK |
Quarterly Revenue Growth (yoy) | 118.79% |
Gross Profit (ttm) | 88.54M SEK |
EBITDA | 49.94M SEK |
Net Income Avi to Common (ttm) | 42.44M SEK |
Diluted EPS (ttm) | 0.69 |
Quarterly Earnings Growth (yoy) | 253.69% |
Balance Sheet
Total Cash (mrq) | 115.4M SEK |
Total Cash Per Share (mrq) | 1.76 SEK |
Total Debt (mrq) | 6.4M SEK |
Total Debt/Equity (mrq) | 3.77 SEK |
Current Ratio (mrq) | 7.773 |
Book Value Per Share (mrq) | 2.597 |
Cash Flow Statement
Operating Cash Flow (ttm) | 47.05M SEK |
Levered Free Cash Flow (ttm) | 29.85M SEK |
Profile of Genovis AB (publ.)
Country | Sweden |
State | N/A |
City | Lund |
Address | Scheelevägen 2 |
ZIP | 220 07 |
Phone | 46 46 10 12 30 |
Website | https://www.genovis.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 37 |
Genovis AB (publ.) designs, develops, and sells tools for development of new treatment methods and diagnostics for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; GingisKHAN, a cysteine protease that digests human IgG1; and FabDELLO, a protease that digests human IgG1. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally; GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology for site-specific and quantitative conjugation of IgG; TransGLYCIT, a platform technology that enables site-specific human IgG glycan remodeling; OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase hydrolyzing the amide bond between the polypeptide asparagine and the innermost GlcNAc; and OpeRATOR, an O-glycan-specific protease. Further, it provides OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; GlycOCATCH, an affinity resin for purification of mucin-type O-glycosylated proteins and peptides; GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a goat polyclonal antibody; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.
Q&A For Genovis AB (publ.) Stock
What is a current GENO.ST stock price?
Genovis AB (publ.) GENO.ST stock price today per share is 30.4 SEK.
How to purchase Genovis AB (publ.) stock?
You can buy GENO.ST shares on the Stockholm exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genovis AB (publ.)?
The stock symbol or ticker of Genovis AB (publ.) is GENO.ST.
Which industry does the Genovis AB (publ.) company belong to?
The Genovis AB (publ.) industry is Biotechnology.
How many shares does Genovis AB (publ.) have in circulation?
The max supply of Genovis AB (publ.) shares is 65.47M.
What is Genovis AB (publ.) Price to Earnings Ratio (PE Ratio)?
Genovis AB (publ.) PE Ratio is 36.62650700 now.
What was Genovis AB (publ.) earnings per share over the trailing 12 months (TTM)?
Genovis AB (publ.) EPS is 0.83 SEK over the trailing 12 months.
Which sector does the Genovis AB (publ.) company belong to?
The Genovis AB (publ.) sector is Healthcare.
Genovis AB (publ.) GENO.ST included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
First North Sweden SEK GI FNSESEKGI | 1956.89 SEK 191.02 USD |
-0.28
|
— — | — — | — — | — - | — — |
First North Sweden EUR GI FNSEEURGI | 1570.14 EUR 1716.38 USD |
-0.77
|
— — | — — | — — | — - | — — |
First North 25 FN25 | 2021.27 EUR 2209.52 USD |
-1.13
|
— — | — — | — — | — - | — — |
First North Health Care GI FN20GI | 917.04 EUR 1002.44 USD |
-1.17
|
— — | — — | — — | — - | — — |
First North All-Share EUR FIRSTNORTHEUR | 97.9 EUR 107.01 USD |
-0.64
|
— — | — — | — — | — - | — — |
First North Sweden SEK PI FNSESEKPI | 1843.91 SEK 179.99 USD |
-0.28
|
— — | — — | — — | — - | — — |
First North Sweden EUR PI FNSEEURPI | 1479.5 EUR 1617.29 USD |
-0.77
|
— — | — — | — — | — - | — — |
First North 25 GI FN25GI | 2138.56 EUR 2337.74 USD |
-1.08
|
— — | — — | — — | — - | — — |
First North Health Care PI FN20PI | 912.9 EUR 997.92 USD |
-1.17
|
— — | — — | — — | — - | — — |
First North All-Share SEK FIRSTNORTHSEK | 123.34 SEK 12.04 USD |
-0.14
|
— — | — — | — — | — - | — — |
First North All-Share DKK FIRSTNORTHDKK | 97.96 DKK 14.36 USD |
-0.62
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}